⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19360528 | 0.79 | ALOX5 (0.33) | — | |
| SCHEMBL8008534 | 0.77 | — | — | |
| SCHEMBL14315288 | 0.75 | — | — | |
| SCHEMBL14140869 | 0.75 | — | — | |
| SCHEMBL644095 | 0.75 | — | — | |
| SCHEMBL21653969 | 0.75 | KDM4E (0.33) | — | |
| SCHEMBL25159076 | 0.73 | CHRNA4 (0.30) | — | |
| SCHEMBL894916 | 0.72 | — | — | |
| SCHEMBL12819582 | 0.71 | — | — | |
| SCHEMBL3148832 | 0.70 | CHRNA4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20190345135-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-11-14 | — | — | US | disclosed |
| WO-2013087581-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | WO | disclosed |
| EP-0248393-B1 | METHOD FOR THE PREPARATION OF ACYLATED HETEROAROMATICS AT ZEOLITHIC CATALYSTS | BASF Aktiengesellschaft (DE) | 1991-08-07 | — | — | EP | disclosed |
| EP-0248393-A1 | Method for the preparation of acylated heteroaromatics at zeolithic catalysts | BASF Aktiengesellschaft (DE) | 1987-12-09 | — | — | EP | disclosed |